METUCHEN, N.J.--(BUSINESS WIRE)--Tevogen Bio, a clinical stage biotechnology company, announced the forthcoming clinical trial of TVGN-489, its investigational allogeneic SARS-CoV-2 specific Cytotoxic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback